EXCLUSIVE: GT Biopharma Announces First Patient Dosed In Phase 1 Trial Of GTB-5550; Company Anticipates Providing Updates In H2 2026 As Enrollment Progresses Through Dose Escalation Cohorts

Benzinga Newsdesk www.benzinga.com Positive 56.1%

Neg 0% Neu 0% Pos 56.1%

Comments

No comments yet. Be the first!